105 related articles for article (PubMed ID: 15102561)
1. Risk of cancer with immunosuppressants compared to immunomodulators in multiple sclerosis: A nested case-control study within the French nationwide claims database.
Bosco-Lévy P; Boutmy E; Guiard E; Foch C; Lassalle R; Favary C; Sabidó M; Blin P
Pharmacoepidemiol Drug Saf; 2023 Dec; 32(12):1421-1430. PubMed ID: 37555380
[TBL] [Abstract][Full Text] [Related]
2. [Treatments for multiple sclerosis: update].
Uginet M; Lefeuvre L; Lerusse J; Pot C; Du Pasquier R; Lalive PH
Rev Med Suisse; 2024 Apr; 20(871):837-842. PubMed ID: 38665104
[TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness of different interferon beta products for relapsing-remitting and secondary progressive multiple sclerosis: Decision analysis based on long-term clinical data and switchable treatments.
Nikfar S; Kebriaeezadeh A; Dinarvand R; Abdollahi M; Sahraian MA; Henry D; Akbari Sari A
Daru; 2013 Jun; 21(1):50. PubMed ID: 23800250
[TBL] [Abstract][Full Text] [Related]
4. Autologous haematopoietic stem cell transplantation for secondary progressive multiple sclerosis: an exploratory cost-effectiveness analysis.
Tappenden P; Saccardi R; Confavreux C; Sharrack B; Muraro PA; Mancardi GL; Kozak T; Farge-Bancel D; Madan J; Rafia R; Akehurst R; Snowden J
Bone Marrow Transplant; 2010 Jun; 45(6):1014-21. PubMed ID: 19855441
[TBL] [Abstract][Full Text] [Related]
5. Modeling the cost-effectiveness of a new treatment for MS (natalizumab) compared with current standard practice in Sweden.
Kobelt G; Berg J; Lindgren P; Jonsson B; Stawiarz L; Hillert J
Mult Scler; 2008 Jun; 14(5):679-90. PubMed ID: 18566030
[TBL] [Abstract][Full Text] [Related]
6. Cost-utility of interferon beta1b in the treatment of patients with active relapsing-remitting or secondary progressive multiple sclerosis.
Kobelt G; Jönsson L; Fredrikson S
Eur J Health Econ; 2003; 4(1):50-9. PubMed ID: 15609169
[TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness of interferon beta-1a, interferon beta-1b, and glatiramer acetate in newly diagnosed non-primary progressive multiple sclerosis.
Prosser LA; Kuntz KM; Bar-Or A; Weinstein MC
Value Health; 2004; 7(5):554-68. PubMed ID: 15367251
[TBL] [Abstract][Full Text] [Related]
8. Genotoxicity of cytokines at chemotherapy-induced 'storm' concentrations in a model of the human bone marrow.
Asurappulige HSH; Thomas AD; Morse HR
Mutagenesis; 2023 Aug; 38(4):201-215. PubMed ID: 37326959
[TBL] [Abstract][Full Text] [Related]
9. A target-specific oral formulation of Doxorubicin-protein nanoparticles: efficacy and safety in hepatocellular cancer.
Golla K; Bhaskar C; Ahmed F; Kondapi AK
J Cancer; 2013; 4(8):644-52. PubMed ID: 24155776
[TBL] [Abstract][Full Text] [Related]
10. Cost-effectiveness of multiple sclerosis disease-modifying therapies: a systematic review of the literature.
Yamamoto D; Campbell JD
Autoimmune Dis; 2012; 2012():784364. PubMed ID: 23304459
[TBL] [Abstract][Full Text] [Related]
11. Serial Assessment of Cardiac Function during and following Mitoxantrone Infusion in 30 Consecutive Patients with Multiple Sclerosis.
Franzen D; Haus A; Hellmich M
Mult Scler Int; 2010; 2010():351045. PubMed ID: 22096623
[TBL] [Abstract][Full Text] [Related]
12. Design of biodegradable nanoparticles for oral delivery of doxorubicin: in vivo pharmacokinetics and toxicity studies in rats.
Kalaria DR; Sharma G; Beniwal V; Ravi Kumar MN
Pharm Res; 2009 Mar; 26(3):492-501. PubMed ID: 18998202
[TBL] [Abstract][Full Text] [Related]
13. The search for a balance between short and long-term treatment outcomes in multiple sclerosis.
Baumhackl U
J Neurol; 2008 Mar; 255 Suppl 1():75-83. PubMed ID: 18317679
[TBL] [Abstract][Full Text] [Related]
14. A comparison of the benefits of mitoxantrone and other recent therapeutic approaches in multiple sclerosis.
Gonsette RE
Expert Opin Pharmacother; 2004 Apr; 5(4):747-65. PubMed ID: 15102561
[TBL] [Abstract][Full Text] [Related]
15. [Aggressive multiple sclerosis. Definition and specific therapeutic indication].
Edan G
Presse Med; 2004 Feb; 33(3):187-91; discussion 192. PubMed ID: 15029034
[TBL] [Abstract][Full Text] [Related]
16. [Immunomodulatory therapy in multiple sclerosis].
Csépány T; Bereczki D
Ideggyogy Sz; 2004 Nov; 57(11-12):401-16. PubMed ID: 15662768
[TBL] [Abstract][Full Text] [Related]
17. Mitoxantrone: a review of its use in multiple sclerosis.
Scott LJ; Figgitt DP
CNS Drugs; 2004; 18(6):379-96. PubMed ID: 15089110
[TBL] [Abstract][Full Text] [Related]
18. Current disease-modifying therapies in multiple sclerosis.
Kieseier BC; Hartung HP
Semin Neurol; 2003 Jun; 23(2):133-46. PubMed ID: 12894379
[TBL] [Abstract][Full Text] [Related]
19. Compared benefit of approved and experimental immunosuppressive therapeutic approaches in multiple sclerosis.
Gonsette RE
Expert Opin Pharmacother; 2007 Jun; 8(8):1103-16. PubMed ID: 17516874
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
